Reuters logo
2 months ago
BRIEF-I'rom Group unit ID Pharma concludes licensing agreement on Sendai Virus Vector technology with U.S.-based Elixirgen
May 16, 2017 / 3:15 AM / 2 months ago

BRIEF-I'rom Group unit ID Pharma concludes licensing agreement on Sendai Virus Vector technology with U.S.-based Elixirgen

1 Min Read

May 16 (Reuters) - I'rom Group Co Ltd

* Says unit ID Pharma Co., Ltd. concluded licensing agreement on Sendai Virus Vector technology With U.S.-based Elixirgen, LLC

* Says unit ID Pharma Co., Ltd. grants Elixirgen non-exclusive rights to use Sendai Virus Vector technology to make products with Elixirgen's genes for research purpose and rights to sell the products

* Says unit ID Pharma Co., Ltd. will receive upfront payment and usage charge from Elixirgen

Source text in Japanese:goo.gl/DMnTFu

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below